Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
That is all the official record says: Ignyta, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
No investor of Ignyta, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 195 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by Ignyta, Inc.
Name
Role
Named in
Bernard E. Parker
Chief Commercial Officer
Nov 2015
Igor P. Bilinsky, Ph.D.
General Manager, Immuno-Oncology and Senior Vice President, Special Operations
Nov 2015
Jacob E. Chacko, M.D.
Chief Financial Officer
Nov 2015
Jonathan E. Lim, M.D.
President and Chief Executive Officer
Nov 2015
Matt E. Onaitis, J.D.
Secretary and General Counsel
Nov 2015
Pratik S. Multani, M.D.
Chief Medical Officer
Nov 2015
Robert E. Wild, Ph.D.
Chief Scientific Officer and SVP, Research
Nov 2015
Valerie S. Harding, Ph.D.
Senior Vice President, Chemistry, Manufacturing and Controls